Impact of Disease-Modifying Treatments on the Longitudinal Evolution of Anti-JCV Antibody Index in Multiple Sclerosis

Impact of Disease-Modifying Treatments on the Longitudinal Evolution of Anti-JCV Antibody Index in Multiple Sclerosis

Background: Risk of natalizumab-related progressive multifocal leukoencephalopathy is associated with the presence of anti-JC-virus (JCV) antibodies.Objective: To investigate the impact of disease-modifying treatments (DMT) on the longitudinal evolution of anti-JCV antibody index.Methods: Patients w...

Full description

Bibliographic Details
Main Authors: Harald Hegen, Janette Walde, Gabriel Bsteh, Michael Auer, Sebastian Wurth, Anne Zinganell, Franziska Di Pauli, Florian Deisenhammer, Thomas Berger
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-10-01
Series:Frontiers in Immunology
Subjects:
JC virus
anti-JCV antibody index
natalizumab
interferon beta
glatiramer acetate
multiple sclerosis
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2018.02435/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2018.02435/full

Similar Items